Medicilon(SH:688202) ZHESHANG SECURITIES·2026-03-09 07:08Investment Rating - The investment rating for the company is "Accumulate" [3] Core Views - The company has significantly reduced its losses in 2025, with a notable revenue acceleration in Q4 2025, achieving a total revenue of 1.161 billion yuan, a year-on-year increase of 11.89%, and a net profit attributable to shareholders of -155 million yuan, a substantial reduction in losses by 176 million yuan compared to the previous year [1][3] - The company signed new orders exceeding expectations, with a total of approximately 1.6 billion yuan in new orders for 2025, representing a year-on-year growth of about 45%. This growth is attributed to strong performance in the domestic safety assessment business in Q4 2025 [2] - The company's overseas revenue has continued to break through, with the proportion of overseas revenue rising to approximately 47% in 2025, indicating a dual-driven growth structure from both domestic and international markets [2] Financial Performance Summary - For 2025, the company is projected to achieve revenues of 1.161 billion yuan, with forecasts for 2026 and 2027 at 1.496 billion yuan and 1.930 billion yuan, respectively, reflecting growth rates of 28.84% and 29.05% [3] - The gross profit margin for 2025 improved by approximately 11 percentage points, and the company expects continued improvement in gross margins in 2026 due to the recovery in order volume and pricing [2] - The net profit attributable to shareholders is forecasted to be -155 million yuan in 2025, with expectations of turning positive in 2026 with a profit of 32 million yuan and further increasing to 185 million yuan in 2027 [3]